Quick Answer
TransMedics Group, Inc. reported Net Income Loss of $190.29 million for the year ending 2025.
- TransMedics Group, Inc. showed an increase of +436.6% in Net Income Loss from 2024 to 2025.
- This data is from TransMedics Group, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$4.90 million | Q2 2018: -$6.12 million | Q3 2018: -$5.11 million | Q4 2018: -$7.64 million | Q1 2019: -$6.90 million | Q2 2019: -$9.20 million | Q3 2019: -$8.28 million | Q4 2019: -$9.18 million | Q1 2020: -$8.85 million | Q2 2020: -$8.50 million | Q3 2020: -$5.09 million | Q4 2020: -$6.31 million | Q1 2021: -$7.92 million | Q2 2021: -$10.67 million | Q3 2021: -$12.96 million | Q1 2022: -$10.56 million | Q2 2022: -$11.52 million | Q3 2022: -$7.43 million | Q1 2023: -$2.64 million | Q2 2023: -$1.00 million | Q3 2023: -$25.42 million | Q1 2024: $12.20 million | Q2 2024: $12.19 million | Q3 2024: $4.22 million | Q1 2025: $25.68 million | Q2 2025: $34.91 million | Q3 2025: $24.32 million.
- Over the full 8 years of available data (2018 to 2025), TransMedics Group, Inc.'s Net Income Loss has grown by 901.0%.
- Historical annual values: Fiscal year 2025: $190.29 million | Fiscal year 2024: $35.46 million | Fiscal year 2023: -$25.03 million | Fiscal year 2022: -$36.23 million | Fiscal year 2021: -$44.22 million | Fiscal year 2020: -$28.75 million | Fiscal year 2019: -$33.55 million | Fiscal year 2018: -$23.76 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: